Cardio Diagnostics Holdings Inc. (CDIO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cardiovascularsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 45/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.19% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges
- Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
- Cardio Diagnostics Holdings (CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans
- Cardio Diagnostics Holdings (CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks
- Cardio Diagnostics Holdings (CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection
- Cardio Diagnostics Holdings (CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians
- Cardio Diagnostics Holdings (CDIO) Targets a $393B Heart Disease Problem With Epigenetics and AI
- Cardio Diagnostics Holdings (CDIO) Aligns With Growing Shift Toward Predictive, Precision Medicine
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cardio Diagnostics Holdings Inc..
Full CDIO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.